Rosuvastatin in Preventing Myonecrosis in Elective Percutaneous Coronary Interventions (PCIs)
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
An increase in cardiac biomarkers has been shown to occur in 5% to 30% of patients after
otherwise successful percutaneous coronary interventions (PCIs)(1) Apart from side-branch
occlusion, intimal dissection and coronary spasm, a possible aetiology of myonecrosis after
PCI might be distal embolization of atherogenic materials from plaque disruption,(2 )causing
obstruction of blood flow at capillary level resulting in micro-infarction.(3,4 )Recent
studies have suggested that pretreatment with Atorvastatin may be associated with a reduction
in infarct size after elective PCI. (5-7 ).Actually the standard pretreatment in patients
undergoing elective coronary-PCI and already treated with aspirin is copidogrel loading dose
administration before procedure.(8,9 ) The investigators hypothesized that a high (40mg)
loading dose of Rosuvastatin administered within 24h before the procedure may be effective in
reducing the rate of periprocedural MI.Therefore, the investigators will conduct a single
center,prospective randomized study to assess whether a single,high (40mg) loading
(within24h)dose of Rosuvastatin is effective in preventing elevation of biomarkers of MI
after elective coronary stent implantation.